Antibe Therapeutics Engages Blaise Group International for Executive Search April 11, 2018 08:00 PM Eastern Daylight Time TORONTO--(BUSINESS WIRE)--Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQB: ATBPF) has engaged Blaise Group International (“Blaise Group”), a leading healthcare-focused executive recruitment agency, to augment its global business development expertise. Blaise Group is a leading retained human capital search and strategic services firm exclusively servicing life science organizations on a global basis. In connection with the agreement, Antibe has granted Blaise Group 151,515 options to purchase common shares of the Company that will vest upon the success of Antibe’s recruitment objective. Each option has an exercise price of $0.495, being today’s closing price of the Company’s shares, and will expire April 11, 2021.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.